Table 2

Univariate analysis of outcome by therapy and CD20 status in de novo precursor B cell ALL: pre-rituximab era

ParameterCD20 negative (N = 133)P*CD20 positive (N = 120)P*P**
No. (%) CR      
    All 111 (84)  107 (89)  NS 
    VAD/CVAD 38 of 56 (68) < .001 45 of 54 (83) .06 .06 
    Hyper-CVAD 73 of 77 (95)  62 of 66 (94)  NS 
No. (%) relapse      
    All 47 of 111 (42)  70 of 107 (65)   
    VAD/CVAD 20 of 38 (53) .01 32 of 45 (71) .02 .08 
    Hyper-CVAD 27 of 73 (37) .01 38 of 62 (61)  .005 
Percent 3-year remission duration      
    All 55  20  < .001 
    VAD/CVAD 42 0.04 18 NS NS 
    Hyper-CVAD 58  22  < .001 
Percent 3-year overall survival      
    All 40  27  .03 
    VAD/CVAD 28 < .001 26 NS NS 
    Hyper-CVAD 60  27  .003 
ParameterCD20 negative (N = 133)P*CD20 positive (N = 120)P*P**
No. (%) CR      
    All 111 (84)  107 (89)  NS 
    VAD/CVAD 38 of 56 (68) < .001 45 of 54 (83) .06 .06 
    Hyper-CVAD 73 of 77 (95)  62 of 66 (94)  NS 
No. (%) relapse      
    All 47 of 111 (42)  70 of 107 (65)   
    VAD/CVAD 20 of 38 (53) .01 32 of 45 (71) .02 .08 
    Hyper-CVAD 27 of 73 (37) .01 38 of 62 (61)  .005 
Percent 3-year remission duration      
    All 55  20  < .001 
    VAD/CVAD 42 0.04 18 NS NS 
    Hyper-CVAD 58  22  < .001 
Percent 3-year overall survival      
    All 40  27  .03 
    VAD/CVAD 28 < .001 26 NS NS 
    Hyper-CVAD 60  27  .003 

CR, complete remission; VAD, vincristine, Adriamycin, dexamethasone; CVAD, cyclophosphamide, VAD; hyper-CVAD, hyper-fractionated cyclophosphamide, vincristine, Adriamycin, dexamethasone.

*

P values represent significance levels of comparison of VAD/CVAD vs hyper-CVAD with CD20 subsets.

**

P values in final column represent significance levels of comparison of CD20 negative versus CD positive with each subset.

Close Modal

or Create an Account

Close Modal
Close Modal